Table of Contents Author Guidelines Submit a Manuscript
Analytical Cellular Pathology
Volume 2015, Article ID 690916, 19 pages
http://dx.doi.org/10.1155/2015/690916
Review Article

Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?

1Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy
2Department of Surgical, Oncological and Oral Sciences, Section of Plastic Surgery, University of Palermo, 90127 Palermo, Italy

Received 30 April 2015; Revised 29 August 2015; Accepted 1 September 2015

Academic Editor: Jérome Devy

Copyright © 2015 Daniele Fanale et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. G. Wang, X. M. Liu, W. Kreis, and D. R. Budman, “The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review,” Cancer Chemotherapy and Pharmacology, vol. 44, no. 5, pp. 355–361, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. J. J. Vicente and L. Wordeman, “Mitosis, microtubule dynamics and the evolution of kinesins,” Experimental Cell Research, vol. 334, no. 1, pp. 61–69, 2015. View at Publisher · View at Google Scholar
  3. A. Desai and T. J. Mitchison, “Microtubule polymerization dynamics,” Annual Review of Cell and Developmental Biology, vol. 13, pp. 83–117, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Bringmann, G. Skiniotis, A. Spilker, S. Kandels-Lewis, I. Vernos, and T. Surrey, “A kinesin-like motor inhibits microtubule dynamic instability,” Science, vol. 303, no. 5663, pp. 1519–1522, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. H. H. Loong and W. Yeo, “Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma,” OncoTargets and Therapy, vol. 7, pp. 575–585, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Klute, E. Nackos, S. Tasaki, D. P. Nguyen, N. H. Bander, and S. T. Tagawa, “Microtubule inhibitor-based antibody-drug conjugates for cancer therapy,” OncoTargets and Therapy, vol. 7, pp. 2227–2236, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Kavallaris, N. M. Verrills, and B. T. Hill, “Anticancer therapy with novel tubulin-interacting drugs,” Drug Resistance Updates, vol. 4, no. 6, pp. 392–401, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Katayama, K. Noguchi, and Y. Sugimoto, “Regulations of P-Glycoprotein/ABCB1/MDR1 in human cancer cells,” New Journal of Science, vol. 2014, Article ID 476974, 10 pages, 2014. View at Publisher · View at Google Scholar
  9. M. Kavallaris, “Microtubules and resistance to tubulin-binding agents,” Nature Reviews Cancer, vol. 10, no. 3, pp. 194–204, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. C. D. Katsetos, M. M. Herman, and S. J. Mörk, “Class III beta-tubulin in human development and cancer,” Cell Motility and the Cytoskeleton, vol. 55, no. 2, pp. 77–96, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Kavallaris, A. S. Tait, B. J. Walsh et al., “Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells,” Cancer Research, vol. 61, no. 15, pp. 5803–5809, 2001. View at Google Scholar · View at Scopus
  12. J. J. Field, A. Kanakkanthara, and J. H. Miller, “Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function,” Bioorganic and Medicinal Chemistry, vol. 22, no. 18, pp. 5050–5059, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. Y.-M. Liu, H.-L. Chen, H.-Y. Lee, and J.-P. Liou, “Tubulin inhibitors: a patent review,” Expert Opinion on Therapeutic Patents, vol. 24, no. 1, pp. 69–88, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Moudi, R. Go, C. Y. S. Yien, and M. Nazre, “Vinca alkaloids,” International Journal of Preventive Medicine, vol. 4, no. 11, pp. 1231–1235, 2013. View at Google Scholar · View at Scopus
  15. R. K. Gregory and I. E. Smith, “Vinorelbine—a clinical review,” British Journal of Cancer, vol. 82, no. 12, pp. 1907–1913, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Vallo, M. Michaelis, F. Rothweiler et al., “Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics,” Translational Oncology, vol. 8, no. 3, pp. 210–216, 2015. View at Publisher · View at Google Scholar
  17. E. Mukhtar, V. M. Adhami, and H. Mukhtar, “Targeting microtubules by natural agents for cancer therapy,” Molecular Cancer Therapeutics, vol. 13, no. 2, pp. 275–284, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. G. V. Subbaraju, T. Golakoti, G. M. L. Patterson, and R. E. Moore, “Three new cryptophycins from Nostoc sp. GSV 224,” Journal of Natural Products, vol. 60, no. 3, pp. 302–305, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Weiss, B. Sammet, and N. Sewald, “Recent approaches for the synthesis of modified cryptophycins,” Natural Product Reports, vol. 30, no. 7, pp. 924–940, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. C. D. Smith and X. Zhang, “Mechanism of action of cryptophycin. Interaction with the Vinca alkaloid domain of tubulin,” Journal of Biological Chemistry, vol. 271, no. 11, pp. 6192–6198, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. S. L. Mooberry, L. Busquets, and G. Tien, “Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent,” International Journal of Cancer, vol. 73, no. 3, pp. 440–448, 1997. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Panda, V. Ananthnarayan, G. Larson, C. Shih, M. A. Jordan, and L. Wilson, “Interaction of the antitumor compound cryptophycin-52 with tubulin,” Biochemistry, vol. 39, no. 46, pp. 14121–14127, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Shih and B. A. Teicher, “Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides,” Current Pharmaceutical Design, vol. 7, no. 13, pp. 1259–1276, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. K. L. Bolduc, S. D. Larsen, and D. H. Sherman, “Efficient, divergent synthesis of cryptophycin unit A analogues,” Chemical Communications, vol. 48, no. 51, pp. 6414–6416, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. T. H. Corbett, F. A. Valeriote, L. Demchik et al., “Preclinical anticancer activity of cryptophycin-8,” Journal of Experimental Therapeutics and Oncology, vol. 1, no. 2, pp. 95–108, 1996. View at Google Scholar · View at Scopus
  26. C. Sessa, K. Weigang-Köhler, O. Pagani et al., “Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule,” European Journal of Cancer, vol. 38, no. 18, pp. 2388–2396, 2002. View at Google Scholar · View at Scopus
  27. C. Dumontet and M. A. Jordan, “Microtubule-binding agents: a dynamic field of cancer therapeutics,” Nature Reviews Drug Discovery, vol. 9, no. 10, pp. 790–803, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. G. D'Agostino, J. del Campo, B. Mellado et al., “A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer,” International Journal of Gynecological Cancer, vol. 16, no. 1, pp. 71–76, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. R. S. Al-Awar, T. H. Corbett, J. E. Ray et al., “Biological evaluation of cryptophycin 52 fragment A analogues: effect of the multidrug resistance ATP binding cassette transporters on antitumor activity,” Molecular Cancer Therapeutics, vol. 3, no. 9, pp. 1061–1067, 2004. View at Google Scholar · View at Scopus
  30. M. M. Wagner, D. C. Paul, C. Shih, M. A. Jordan, L. Wilson, and D. C. Williams, “In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines,” Cancer Chemotherapy and Pharmacology, vol. 43, no. 2, pp. 115–125, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. J. P. Stevenson, W. Sun, M. Gallagher et al., “Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days,” Clinical Cancer Research, vol. 8, no. 8, pp. 2524–2529, 2002. View at Google Scholar · View at Scopus
  32. M. J. Edelman, D. R. Gandara, P. Hausner et al., “Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer,” Lung Cancer, vol. 39, no. 2, pp. 197–199, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Corbett, L. Polin, P. LoRusso et al., “In Vivo methods for screening and preclinical testing,” in Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, pp. 99–123, Springer, Berlin, Germany, 2004. View at Publisher · View at Google Scholar
  34. J. Liang, R. E. Moore, E. D. Moher et al., “Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors,” Investigational New Drugs, vol. 23, no. 3, pp. 213–224, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Menon, E. Alvarez, P. Forler et al., “Antitumor activity of cryptophycins: effect of infusion time and combination studies,” Cancer Chemotherapy and Pharmacology, vol. 46, no. 2, pp. 142–149, 2000. View at Publisher · View at Google Scholar
  36. R. R. Boinpally, L. Polin, S.-L. Zhou et al., “Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors,” Cancer Chemotherapy and Pharmacology, vol. 52, no. 1, pp. 25–33, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Griggs, J. C. Metcalfe, and R. Hesketh, “Targeting tumour vasculature: the development of combretastatin A4,” The Lancet Oncology, vol. 2, no. 2, pp. 82–87, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. G. G. Dark, S. A. Hill, V. E. Prise, G. M. Tozer, G. R. Pettit, and D. J. Chaplin, “Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature,” Cancer Research, vol. 57, no. 10, pp. 1829–1834, 1997. View at Google Scholar · View at Scopus
  39. G. M. Tozer, C. Kanthou, C. S. Parkins, and S. A. Hill, “The biology of the combretastatins as tumour vascular targeting agents,” International Journal of Experimental Pathology, vol. 83, no. 1, pp. 21–38, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. S. M. Nabha, R. M. Mohammad, M. H. Dandashi et al., “Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage,” Clinical Cancer Research, vol. 8, no. 8, pp. 2735–2741, 2002. View at Google Scholar · View at Scopus
  41. I. Vitale, A. Antoccia, C. Cenciarelli et al., “Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells,” Apoptosis, vol. 12, no. 1, pp. 155–166, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. D. E. Friesen, K. H. Barakat, V. Semenchenko et al., “Discovery of small molecule inhibitors that interact with γ-tubulin,” Chemical Biology and Drug Design, vol. 79, no. 5, pp. 639–652, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. C. D. Katsetos, G. Reddy, E. Dráberová et al., “Altered cellular distribution and subcellular sorting of γ-tubulin in diffuse astrocytic gliomas and human glioblastoma cell lines,” Journal of Neuropathology and Experimental Neurology, vol. 65, no. 5, pp. 465–477, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. V. Caracciolo, L. D'Agostino, E. Dráberová et al., “Differential expression and cellular distribution of gamma-tubulin and betaIII-tubulin in medulloblastomas and human medulloblastoma cell lines,” Journal of Cellular Physiology, vol. 223, no. 2, pp. 519–529, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. N. F. Maounis, E. Dráberová, E. Mahera et al., “Overexpression of γ-tubulin in non-small cell lung cancer,” Histology and Histopathology, vol. 27, no. 9, pp. 1183–1194, 2012. View at Google Scholar · View at Scopus
  46. T. Liu, Y. Niu, Y. Yu, Y. Liu, and F. Zhang, “Increased γ-tubulin expression and P16INK4A promoter methylation occur together in preinvasive lesions and carcinomas of the breast,” Annals of Oncology, vol. 20, no. 3, pp. 441–448, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. M. M. Mita, L. Sargsyan, A. C. Mita, and M. Spear, “Vascular-disrupting agents in oncology,” Expert Opinion on Investigational Drugs, vol. 22, no. 3, pp. 317–328, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. G. M. Tozer, V. E. Prise, J. Wilson et al., “Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues,” Cancer Research, vol. 59, no. 7, pp. 1626–1634, 1999. View at Google Scholar · View at Scopus
  49. W. Landuyt, O. Verdoes, D. O. Darius et al., “Vascular targeting of solid tumoursa major ‘inverse’ volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas,” European Journal of Cancer, vol. 36, no. 14, pp. 1833–1843, 2000. View at Publisher · View at Google Scholar · View at Scopus
  50. D. J. Chaplin and S. A. Hill, “The development of combretastatin A4 phosphate as a vascular targeting agent,” International Journal of Radiation Oncology Biology Physics, vol. 54, no. 5, pp. 1491–1496, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. D. A. Beauregard, S. A. Hill, D. J. Chaplin, and K. M. Brindle, “The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability,” Cancer Research, vol. 61, no. 18, pp. 6811–6815, 2001. View at Google Scholar · View at Scopus
  52. C. Kanthou and G. M. Tozer, “The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells,” Blood, vol. 99, no. 6, pp. 2060–2069, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Hussain, M. Steimle, H. Hoppeler, O. Baum, and S. Egginton, “The vascular-disrupting agent combretastatin impairs splitting and sprouting forms of physiological angiogenesis,” Microcirculation, vol. 19, no. 4, pp. 296–305, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. L. Vincent, P. Kermani, L. M. Young et al., “Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling,” Journal of Clinical Investigation, vol. 115, no. 11, pp. 2992–3006, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. A. C. Brooks, C. Kanthou, I. H. Cook et al., “The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro,” Anticancer Research, vol. 23, no. 4, pp. 3199–3206, 2003. View at Google Scholar · View at Scopus
  56. G. U. Dachs, A. J. Steele, C. Coralli et al., “Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression,” BMC Cancer, vol. 6, article 280, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. L. Li, A. M. Rojiani, and D. W. Siemann, “Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma,” Acta Oncologica, vol. 41, no. 1, pp. 91–97, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. S. A. Hill, D. J. Chaplin, G. Lewis, and G. M. Tozer, “Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models,” International Journal of Cancer, vol. 102, no. 1, pp. 70–74, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. M. R. Horsman and R. Murata, “Combination of vascular targeting agents with thermal or radiation therapy,” International Journal of Radiation Oncology Biology Physics, vol. 54, no. 5, pp. 1518–1523, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. K. J. Lankester, R. J. Maxwell, R. B. Pedley et al., “Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down,” International Journal of Oncology, vol. 30, no. 2, pp. 453–460, 2007. View at Google Scholar · View at Scopus
  61. H. Wildiers, B. Ahmed, G. Guetens et al., “Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence,” European Journal of Cancer, vol. 40, no. 2, pp. 284–290, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. S. L. Young and D. J. Chaplin, “Combretastatin A4 phosphate: Background and current clinical status,” Expert Opinion on Investigational Drugs, vol. 13, no. 9, pp. 1171–1182, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. J. H. Bilenker, K. T. Flaherty, M. Rosen et al., “Phase I trial of combretastatin A-4 phosphate with carboplatin,” Clinical Cancer Research, vol. 11, no. 4, pp. 1527–1533, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. M. M. Cooney, T. Radivoyevitch, A. Dowlati et al., “Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer,” Clinical Cancer Research, vol. 10, no. 1, part 1, pp. 96–100, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. D. W. Siemann, D. J. Chaplin, and P. A. Walicke, “A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P),” Expert Opinion on Investigational Drugs, vol. 18, no. 2, pp. 189–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. R. Granata, L. D. Locati, and L. Licitra, “Fosbretabulin for the treatment of anaplastic thyroid cancer,” Future Oncology, vol. 10, no. 13, pp. 2015–2021, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Dowlati, K. Robertson, M. Cooney et al., “A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer,” Cancer Research, vol. 62, no. 12, pp. 3408–3416, 2002. View at Google Scholar · View at Scopus
  68. H. L. Anderson, J. T. Yap, M. P. Miller, A. Robbins, T. Jones, and P. M. Price, “Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate,” Journal of Clinical Oncology, vol. 21, no. 15, pp. 2823–2830, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. G. J. S. Rustin, S. M. Galbraith, H. Anderson et al., “Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results,” Journal of Clinical Oncology, vol. 21, no. 15, pp. 2815–2822, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. J. P. Stevenson, M. Rosen, W. Sun et al., “Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow,” Journal of Clinical Oncology, vol. 21, no. 23, pp. 4428–4438, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. R. Nallamothu, G. C. Wood, M. F. Kiani, B. M. Moore, F. P. Horton, and L. A. Thoma, “A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies,” PDA Journal of Pharmaceutical Science and Technology, vol. 60, no. 3, pp. 144–155, 2006. View at Google Scholar · View at Scopus
  72. J. A. Sosa, R. Elisei, B. Jarzab et al., “Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma,” Thyroid, vol. 24, no. 2, pp. 232–240, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. G. Korpanty, E. Smyth, and D. N. Carney, “Update on anti-angiogenic therapy in non-small cell lung cancer: are we making progress?” Journal of Thoracic Disease, vol. 3, no. 1, pp. 19–29, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Hua, Y. Sheng, K. G. Pinney et al., “Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate,” Anticancer Research, vol. 23, no. 2, pp. 1433–1440, 2003. View at Google Scholar · View at Scopus
  75. Y. Sheng, J. Hua, K. G. Pinney et al., “Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis,” International Journal of Cancer, vol. 111, no. 4, pp. 604–610, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. K. Staflin, S. Järnum, J. Hua, G. Honeth, P. Kannisto, and M. Lindvall, “Combretastatin A-1 phosphate potentiates the antitumor activity of carboplatin and paclitaxel in a severe combined immunodeficiency disease (SCID) mouse model of human ovarian carcinoma,” International Journal of Gynecological Cancer, vol. 16, no. 4, pp. 1557–1564, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. I. G. Kirwan, P. M. Loadman, D. J. Swaine et al., “Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate,” Clinical Cancer Research, vol. 10, no. 4, pp. 1446–1453, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. D. M. Patterson, M. Zweifel, M. R. Middleton et al., “Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors,” Clinical Cancer Research, vol. 18, no. 5, pp. 1415–1425, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. J. Cummings, M. Zweifel, N. Smith et al., “Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial,” British Journal of Cancer, vol. 106, no. 11, pp. 1766–1771, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Kumar, S. Mehndiratta, K. Nepali et al., “Novel indole-bearing combretastatin analogues as tubulin polymerization inhibitors,” Organic and Medicinal Chemistry Letters, vol. 3, no. 1, article 3, 2013. View at Publisher · View at Google Scholar
  81. S. Zheng, Q. Zhong, M. Mottamal et al., “Design, synthesis, and biological evaluation of novel pyridine-bridged analogues of combretastatin-A4 as anticancer agents,” Journal of Medicinal Chemistry, vol. 57, no. 8, pp. 3369–3381, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. K. Hori, S. Saito, Y. Sato, and K. Kubota, “Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect,” Medical Science Monitor, vol. 7, no. 1, pp. 26–33, 2001. View at Google Scholar · View at Scopus
  83. A. Delmonte and C. Sessa, “AVE8062: a new combretastatin derivative vascular disrupting agent,” Expert Opinion on Investigational Drugs, vol. 18, no. 10, pp. 1541–1548, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Hori and S. Saito, “Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis,” British Journal of Cancer, vol. 89, no. 7, pp. 1334–1344, 2003. View at Publisher · View at Google Scholar · View at Scopus
  85. Y. Morinaga, Y. Suga, S. Ehara, K. Harada, Y. Nihei, and M. Suzuki, “Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo,” Cancer Science, vol. 94, no. 2, pp. 200–204, 2003. View at Publisher · View at Google Scholar · View at Scopus
  86. J. Y. Blay, Z. Pápai, A. W. Tolcher et al., “Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial,” The Lancet Oncology, vol. 16, no. 5, pp. 531–540, 2015. View at Publisher · View at Google Scholar
  87. J. Poncet, “The dolastatins, a family of promising antineoplastic agents,” Current Pharmaceutical Design, vol. 5, no. 3, pp. 139–162, 1999. View at Google Scholar · View at Scopus
  88. F. Erik and S. Jayaram, “The dolastatins,” in Anticancer Agents from Natural Products, pp. 263–290, CRC Press, 2nd edition, 2011. View at Google Scholar
  89. L. M. Krug, V. A. Miller, G. P. Kalemkerian et al., “Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer,” Annals of Oncology, vol. 11, no. 2, pp. 227–228, 2000. View at Publisher · View at Google Scholar · View at Scopus
  90. K. Margolin, J. Longmate, T. W. Synold et al., “Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium,” Investigational New Drugs, vol. 19, no. 4, pp. 335–340, 2001. View at Publisher · View at Google Scholar · View at Scopus
  91. E. D. Saad, E. H. Kraut, P. M. Hoff et al., “Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer,” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 25, no. 5, pp. 451–453, 2002. View at Publisher · View at Google Scholar · View at Scopus
  92. M. A. Hoffman, J. A. Blessing, and S. S. Lentz, “A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group Study,” Gynecologic Oncology, vol. 89, no. 1, pp. 95–98, 2003. View at Publisher · View at Google Scholar · View at Scopus
  93. U. Vaishampayan, M. Glode, W. Du et al., “Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma,” Clinical Cancer Research, vol. 6, no. 11, pp. 4205–4208, 2000. View at Google Scholar · View at Scopus
  94. E. A. Perez, D. W. Hillman, P. A. Fishkin et al., “Phase II trial of dolastatin-10 in patients with advanced breast cancer,” Investigational New Drugs, vol. 23, no. 3, pp. 257–261, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. H. L. Kindler, P. K. Tothy, R. Wolff et al., “Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers,” Investigational New Drugs, vol. 23, no. 5, pp. 489–493, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. M. von Mehren, S. P. Balcerzak, A. S. Kraft et al., “Phase II trial of dolastatin-10, a novel anti-tubulin agent, in metastatic soft tissue sarcomas,” Sarcoma, vol. 8, no. 4, pp. 107–111, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. T. L. Simmons, E. Andrianasolo, K. McPhail, P. Flatt, and W. H. Gerwick, “Marine natural products as anticancer drugs,” Molecular Cancer Therapeutics, vol. 4, no. 2, pp. 333–342, 2005. View at Google Scholar · View at Scopus
  98. J. Watanabe, T. Natsume, N. Fujio, K. Miyasaka, and M. Kobayashi, “Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent,” Apoptosis, vol. 5, no. 4, pp. 345–353, 2000. View at Publisher · View at Google Scholar · View at Scopus
  99. P. Schöffski, B. Thate, G. Beutel et al., “Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer,” Annals of Oncology, vol. 15, no. 4, pp. 671–679, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. M. J. A. de Jonge, A. van der Gaast, A. S. T. Planting et al., “Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors,” Clinical Cancer Research, vol. 11, no. 10, pp. 3806–3813, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. K. Tamura, K. Nakagawa, T. Kurata et al., “Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses,” Cancer Chemotherapy and Pharmacology, vol. 60, no. 2, pp. 285–293, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Greystoke, S. Blagden, A. L. Thomas et al., “A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours,” Annals of Oncology, vol. 17, no. 8, pp. 1313–1319, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. J. Horti, E. Juhasz, Z. Monostori, K. Maeda, S. Eckhardt, and I. Bodrogi, “Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer,” Cancer Chemotherapy and Pharmacology, vol. 62, no. 1, pp. 173–180, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Patel, M. L. Keohan, M. W. Saif et al., “Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy,” Cancer, vol. 107, no. 12, pp. 2881–2887, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. G. J. Riely, S. Gadgeel, I. Rothman et al., “A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy,” Lung Cancer, vol. 55, no. 2, pp. 181–185, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. Z. Cruz-Monserrate, J. T. Mullaney, P. G. Harran, G. R. Pettit, and E. Hamel, “Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography,” European Journal of Biochemistry, vol. 270, no. 18, pp. 3822–3828, 2003. View at Publisher · View at Google Scholar · View at Scopus
  107. K. G. Steube, D. Grunicke, T. Pietsch, S. M. Gignac, G. R. Pettit, and H. G. Drexler, “Dolastatin 10 and dolastatin 15: effects of two natural peptides on growth and differentiation of leukemia cells,” Leukemia, vol. 6, no. 10, pp. 1048–1053, 1992. View at Google Scholar · View at Scopus
  108. M. A. Ali, R. Rosati, G. R. Pettit, and G. P. Kalemkerian, “Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines,” Anticancer Research, vol. 18, no. 2, pp. 1021–1026, 1998. View at Google Scholar · View at Scopus
  109. M. Sato, M. Sagawa, T. Nakazato, Y. Ikeda, and M. Kizaki, “A natural peptide, dolastatin 15, induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cells,” International Journal of Oncology, vol. 30, no. 6, pp. 1453–1459, 2007. View at Google Scholar · View at Scopus
  110. R. L. Piekarz, R. Frye, M. Turner et al., “Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma,” Journal of Clinical Oncology, vol. 27, no. 32, pp. 5410–5417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. S. E. Bates, R. Eisch, A. Ling et al., “Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data,” British Journal of Haematology, vol. 170, no. 1, pp. 96–109, 2015. View at Publisher · View at Google Scholar
  112. M. de Arruda, C. A. Cocchiaro, C. M. Nelson et al., “LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis,” Cancer Research, vol. 55, no. 14, pp. 3085–3092, 1995. View at Google Scholar · View at Scopus
  113. M. A. Jordan, D. Walker, M. de Arruda, T. Barlozzari, and D. Panda, “Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action,” Biochemistry, vol. 37, no. 50, pp. 17571–17578, 1998. View at Publisher · View at Google Scholar · View at Scopus
  114. M. A. Villalona-Calero, S. D. Baker, L. Hammond et al., “Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies,” Journal of Clinical Oncology, vol. 16, no. 8, pp. 2770–2779, 1998. View at Google Scholar · View at Scopus
  115. K. Mross, W. E. Berdel, H. H. Fiebig, R. Velagapudi, I. M. von Broen, and C. Unger, “Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematologie (APOH) Group of the German Cancer Society,” Annals of Oncology, vol. 9, no. 12, pp. 1323–1330, 1998. View at Publisher · View at Google Scholar · View at Scopus
  116. J. G. Supko, T. J. Lynch, J. W. Clark et al., “A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion,” Cancer Chemotherapy and Pharmacology, vol. 46, no. 4, pp. 319–328, 2000. View at Publisher · View at Google Scholar · View at Scopus
  117. J. Smyth, M. E. Boneterre, J. Schellens et al., “Activity of the dolastatin analogue, LU103793, in malignant melanoma,” Annals of Oncology, vol. 12, no. 4, pp. 509–511, 2001. View at Publisher · View at Google Scholar · View at Scopus
  118. P. Kerbrat, V. Dieras, N. Pavlidis, A. Ravaud, J. Wanders, and P. Fumoleau, “Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer,” European Journal of Cancer, vol. 39, no. 3, pp. 317–320, 2003. View at Publisher · View at Google Scholar · View at Scopus
  119. R. S. Marks, D. L. Graham, J. A. Sloan et al., “A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer,” American Journal of Clinical Oncology, vol. 26, no. 4, pp. 336–337, 2003. View at Publisher · View at Google Scholar · View at Scopus
  120. K. K. Rasila and C. Verschraegen, “Tasidotin HCI genzyme,” Current Opinion in Investigational Drugs, vol. 6, no. 6, pp. 631–638, 2005. View at Google Scholar · View at Scopus
  121. R. Bai, M. C. Edler, P. L. Bonate et al., “Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity,” Molecular Pharmacology, vol. 75, no. 1, pp. 218–226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. A. Ray, T. Okouneva, T. Manna et al., “Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate,” Cancer Research, vol. 67, no. 8, pp. 3767–3776, 2007. View at Publisher · View at Google Scholar · View at Scopus
  123. V. Garg, W. Zhang, P. Gidwani, M. Kim, and E. A. Kolb, “Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma,” Clinical Cancer Research, vol. 13, no. 18, part 1, pp. 5446–5454, 2007. View at Publisher · View at Google Scholar · View at Scopus
  124. S. Ebbinghaus, E. Rubin, E. Hersh et al., “A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors,” Clinical Cancer Research, vol. 11, no. 21, pp. 7807–7816, 2005. View at Publisher · View at Google Scholar · View at Scopus
  125. C. Cunningham, L. J. Appleman, M. Kirvan-Visovatti et al., “Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors,” Clinical Cancer Research, vol. 11, no. 21, pp. 7825–7833, 2005. View at Publisher · View at Google Scholar · View at Scopus
  126. A. C. Mita, L. A. Hammond, P. L. Bonate et al., “Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors,” Clinical Cancer Research, vol. 12, no. 17, pp. 5207–5215, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. H. R. Hendriks, J. Plowman, D. P. Berger et al., “Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent,” Annals of Oncology, vol. 3, no. 9, pp. 755–763, 1992. View at Google Scholar · View at Scopus
  128. A. E. Prota, K. Bargsten, J. F. Diaz et al., “A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 38, pp. 13817–13821, 2014. View at Publisher · View at Google Scholar · View at Scopus
  129. T. Tsuruo, T. Oh-hara, H. Iida et al., “Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and the vincristine-resistant sublines,” Cancer Research, vol. 46, no. 1, pp. 381–385, 1986. View at Google Scholar · View at Scopus
  130. D. Bissett, M. A. Graham, A. Setanoians et al., “Phase I and pharmacokinetic study of rhizoxin,” Cancer Research, vol. 52, no. 10, pp. 2894–2898, 1992. View at Google Scholar · View at Scopus
  131. D. J. Kerr, G. J. Rustin, S. B. Kaye et al., “Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer,” British Journal of Cancer, vol. 72, no. 5, pp. 1267–1269, 1995. View at Publisher · View at Google Scholar · View at Scopus
  132. A. R. Hanauske, G. Catimel, S. Aamdal et al., “Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC early clinical trials group,” British Journal of Cancer, vol. 73, no. 3, pp. 397–399, 1996. View at Google Scholar
  133. J. Verweij, J. Wanders, T. Gil et al., “Phase II study of rhizoxin in squamous cell head and neck cancer,” British Journal of Cancer, vol. 73, no. 3, pp. 400–402, 1996. View at Publisher · View at Google Scholar · View at Scopus
  134. S. Kaplan, A. R. Hanauske, N. Pavlidis et al., “Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group,” British Journal of Cancer, vol. 73, no. 3, pp. 403–405, 1996. View at Publisher · View at Google Scholar · View at Scopus
  135. H. L. McLeod, L. S. Murray, J. Wanders et al., “Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups,” British Journal of Cancer, vol. 74, no. 12, pp. 1944–1948, 1996. View at Publisher · View at Google Scholar
  136. A. W. Tolcher, C. Aylesworth, J. Rizzo et al., “A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors,” Annals of Oncology, vol. 11, no. 3, pp. 333–338, 2000. View at Publisher · View at Google Scholar · View at Scopus
  137. G. Bacher, B. Nickel, P. Emig et al., “D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity,” Cancer Research, vol. 61, no. 1, pp. 392–399, 2001. View at Google Scholar · View at Scopus
  138. A. Wienecke and G. Bacher, “Indibulin, a novel microtubule inhibitor, discriminates between mature neuronal and nonneuronal tubulin,” Cancer Research, vol. 69, no. 1, pp. 171–177, 2009. View at Publisher · View at Google Scholar · View at Scopus
  139. H. Ito, T. Kanzawa, S. Kondo, and Y. Kondo, “Microtubule inhibitor D-24851 induces p53-independent apoptotic cell death in malignant glioma cells through Bcl-2 phosphorylation and Bax translocation,” International Journal of Oncology, vol. 26, no. 3, pp. 589–596, 2005. View at Google Scholar · View at Scopus
  140. E. Stokvis, L. G. A. H. Nan-Offeringa, M. Ouwehand et al., “Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry,” Rapid Communications in Mass Spectrometry, vol. 18, no. 13, pp. 1465–1471, 2004. View at Publisher · View at Google Scholar · View at Scopus
  141. I. E. L. M. Kuppens, P. O. Witteveen, M. Schot et al., “Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors,” Investigational New Drugs, vol. 25, no. 3, pp. 227–235, 2007. View at Publisher · View at Google Scholar · View at Scopus
  142. T.-H. Huang, S.-J. Chiu, P.-H. Chiang et al., “Antiproliferative effects of N-heterocyclic indolyl glyoxylamide derivatives on human lung cancer cells,” Anticancer Research, vol. 31, no. 10, pp. 3407–3415, 2011. View at Google Scholar · View at Scopus
  143. V. K. W. Wong, P. Chiu, S. S. M. Chung et al., “Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo,” Clinical Cancer Research, vol. 11, no. 16, pp. 6002–6011, 2005. View at Publisher · View at Google Scholar · View at Scopus
  144. X. Gong, M. Wang, S.-I. Tashiro, S. Onodera, and T. Ikejima, “Involvement of JNK-initiated p53 accumulation and phosphorylation of p53 in pseudolaric acid B induced cell death,” Experimental and Molecular Medicine, vol. 38, no. 4, pp. 428–434, 2006. View at Publisher · View at Google Scholar · View at Scopus
  145. W.-F. Tan, X.-W. Zhang, M.-H. Li et al., “Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect,” European Journal of Pharmacology, vol. 499, no. 3, pp. 219–228, 2004. View at Publisher · View at Google Scholar · View at Scopus
  146. M.-H. Li, Z.-H. Miao, W.-F. Tan et al., “Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation,” Clinical Cancer Research, vol. 10, no. 24, pp. 8266–8274, 2004. View at Publisher · View at Google Scholar · View at Scopus
  147. Y.-G. Tong, X.-W. Zhang, M.-Y. Geng et al., “Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin,” Molecular Pharmacology, vol. 69, no. 4, pp. 1226–1233, 2006. View at Publisher · View at Google Scholar · View at Scopus
  148. Q. Sun and Y. Li, “The inhibitory effect of pseudolaric acid B on gastric cancer and multidrug resistance via Cox-2/PKC-α/P-gp pathway,” PLoS ONE, vol. 9, no. 9, Article ID e107830, 2014. View at Publisher · View at Google Scholar · View at Scopus
  149. F. Yu, K. Li, S. Chen, Y. Liu, and Y. Li, “Pseudolaric acid B circumvents multidrug resistance phenotype in human gastric cancer SGC7901/ADR cells by downregulating Cox-2 and P-gp expression,” Cell Biochemistry and Biophysics, vol. 71, no. 1, pp. 119–126, 2015. View at Publisher · View at Google Scholar · View at Scopus
  150. H. J. Jung, J. S. Shim, H. B. Lee et al., “Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo,” Biochemical and Biophysical Research Communications, vol. 353, no. 2, pp. 376–380, 2007. View at Publisher · View at Google Scholar · View at Scopus
  151. A. Kiselyov, K. V. Balakin, S. E. Tkachenko, N. Savchuk, and A. V. Ivachtchenko, “Recent progress in discovery and development of antimitotic agents,” Anti-Cancer Agents in Medicinal Chemistry, vol. 7, no. 2, pp. 189–208, 2007. View at Publisher · View at Google Scholar · View at Scopus
  152. C. de Ines, D. Leynadier, I. Barasoain et al., “Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8- dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863,” Cancer Research, vol. 54, no. 1, pp. 75–84, 1994. View at Google Scholar · View at Scopus
  153. K. E. Hook, S. A. Przybranowski, and W. R. Leopold, “Cellular transport of CI-980,” Investigational New Drugs, vol. 14, no. 4, pp. 341–347, 1996. View at Google Scholar · View at Scopus
  154. N. T. Sklarin, C. D. Lathia, L. Benson et al., “A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors,” Investigational New Drugs, vol. 15, no. 3, pp. 235–246, 1997. View at Publisher · View at Google Scholar · View at Scopus
  155. C. A. Meyers, A. P. Kudelka, C. A. Conrad, C. K. Gelke, W. Grove, and R. Pazdur, “Neurotoxicity of CI-980, a novel mitotic inhibitor,” Clinical Cancer Research, vol. 3, no. 3, pp. 419–422, 1997. View at Google Scholar · View at Scopus
  156. M. L. Bernstein, S. Baruchel, S. Devine et al., “Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study,” Journal of Pediatric Hematology/Oncology, vol. 21, no. 6, pp. 494–500, 1999. View at Publisher · View at Google Scholar · View at Scopus
  157. E. K. Rowinsky, G. S. Long, D. A. Noe et al., “Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent,” Clinical Cancer Research, vol. 3, no. 3, pp. 401–407, 1997. View at Google Scholar · View at Scopus
  158. R. Pazdur, C. Meyers, E. Diaz-Canton et al., “Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity,” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 20, no. 6, pp. 573–576, 1997. View at Publisher · View at Google Scholar · View at Scopus
  159. J. P. Thomas, T. Moore, E. H. Kraut, S. P. Balcerzak, S. Galloway, and D. D. Vandre, “A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study,” Cancer Investigation, vol. 20, no. 2, pp. 192–198, 2002. View at Publisher · View at Google Scholar · View at Scopus
  160. A. P. Kudelka, A. Hasenburg, C. F. Verschraegen et al., “Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma,” Anti-Cancer Drugs, vol. 9, no. 5, pp. 405–409, 1998. View at Publisher · View at Google Scholar · View at Scopus
  161. B. Shan, J. C. Medina, E. Santha et al., “Selective, covalent modification of β-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 10, pp. 5686–5691, 1999. View at Publisher · View at Google Scholar · View at Scopus
  162. S. M. Rubenstein, V. Baichwal, H. Beckmann et al., “Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier,” Journal of Medicinal Chemistry, vol. 44, no. 22, pp. 3599–3605, 2001. View at Publisher · View at Google Scholar · View at Scopus
  163. R. C. Donehower, G. Schwartz, A. C. Wolf et al., “Phase I and pharmacokinetic study of T138067 administered as a weekly 3-hour infusion,” Clinical Cancer Research, vol. 6, pp. 4578s–4579s, 2000. View at Google Scholar
  164. G. Schwartz, E. K. Rowinsky, P. O'Dwyer et al., “Phase I and pharmacokinetic study of T138067, a synthetic microtubule depolymerizing agent, administered as a 3-hour infusion daily x 5 every 3 weeks,” Clinical Cancer Research, vol. 6, pp. 4579s–4579s, 2000. View at Google Scholar
  165. S. Kirby, S. Z. Gertler, W. Mason et al., “Phase 2 study of T138067-sodium in patients with malignant glioma: trial of the National Cancer Institute of Canada Clinical Trials Group,” Neuro-Oncology, vol. 7, no. 2, pp. 183–188, 2005. View at Publisher · View at Google Scholar · View at Scopus
  166. J. D. Berlin, A. Venook, E. Bergsland, M. Rothenberg, A. C. Lockhart, and L. Rosen, “Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma,” Clinical Colorectal Cancer, vol. 7, no. 1, pp. 44–47, 2008. View at Publisher · View at Google Scholar · View at Scopus
  167. K. A. Gelmon, K. Belanger, D. Soulieres et al., “A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130,” Investigational New Drugs, vol. 23, no. 5, pp. 445–453, 2005. View at Publisher · View at Google Scholar · View at Scopus
  168. K. Yoshimatsu, A. Yamaguchi, H. Yoshino, N. Koyanagi, and K. Kitoh, “Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin,” Cancer Research, vol. 57, no. 15, pp. 3208–3213, 1997. View at Google Scholar · View at Scopus
  169. Y. Funahashi, N. Koyanagi, and K. Kitoh, “Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine Colon 38 tumor,” Cancer Chemotherapy and Pharmacology, vol. 47, no. 2, pp. 179–184, 2001. View at Publisher · View at Google Scholar · View at Scopus
  170. Y. Iwamoto, K. Nishio, H. Fukumoto, K. Yoshimatsu, M. Yamakido, and N. Saijo, “Preferential binding of E7010 to murine β3-tubulin and decreased β3-tubulin in E7010-resistant cell lines,” Japanese Journal of Cancer Research, vol. 89, no. 9, pp. 954–962, 1998. View at Publisher · View at Google Scholar · View at Scopus
  171. K. Hayakawa, T. Tashiro, K. Sato et al., “Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats: 17) testicular toxicity of e7010, a sulfonamide tubulin polymerization inhibitor,” Journal of Toxicological Sciences, vol. 25, pp. 173–178, 2000. View at Publisher · View at Google Scholar · View at Scopus
  172. Y. Nihei, M. Suzuki, A. Okano et al., “Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy,” Japanese Journal of Cancer Research, vol. 90, no. 12, pp. 1387–1395, 1999. View at Publisher · View at Google Scholar · View at Scopus
  173. K. Yamamoto, K. Noda, A. Yoshimura, M. Fukuoka, K. Furuse, and H. Niitani, “Phase I study of E7010,” Cancer Chemotherapy and Pharmacology, vol. 42, no. 2, pp. 127–134, 1998. View at Publisher · View at Google Scholar · View at Scopus
  174. K. W. L. Yee, A. Hagey, S. Verstovsek et al., “Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies,” Clinical Cancer Research, vol. 11, no. 18, pp. 6615–6624, 2005. View at Publisher · View at Google Scholar · View at Scopus
  175. E. Fox, J. M. Maris, B. C. Widemann et al., “A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors,” Clinical Cancer Research, vol. 14, no. 4, pp. 1111–1115, 2008. View at Publisher · View at Google Scholar · View at Scopus
  176. A. M. Mauer, E. E. W. Cohen, P. C. Ma et al., “A phase II study of ABT-751 in patients with advanced non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 3, no. 6, pp. 631–636, 2008. View at Publisher · View at Google Scholar · View at Scopus
  177. J. Michels, S. L. Ellard, L. Le et al., “A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer,” Annals of Oncology, vol. 21, no. 2, pp. 305–311, 2010. View at Publisher · View at Google Scholar · View at Scopus
  178. C. M. Rudin, A. Mauer, M. Smakal et al., “Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 29, no. 8, pp. 1075–1082, 2011. View at Publisher · View at Google Scholar · View at Scopus
  179. T. Ma, A. D. Fuld, J. R. Rigas et al., “A phase i trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients,” Chemotherapy, vol. 58, no. 4, pp. 321–329, 2012. View at Publisher · View at Google Scholar · View at Scopus
  180. M. C. Wani, H. L. Taylor, M. E. Wall, P. Coggon, and A. T. McPhail, “Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia,” Journal of the American Chemical Society, vol. 93, no. 9, pp. 2325–2327, 1971. View at Publisher · View at Google Scholar · View at Scopus
  181. M. Kavallaris, D. Y.-S. Kuo, C. A. Burkhart et al., “Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes,” The Journal of Clinical Investigation, vol. 100, no. 5, pp. 1282–1293, 1997. View at Publisher · View at Google Scholar · View at Scopus
  182. J. A. McCarroll, P. P. Gan, M. Liu, and M. Kavallaris, “BetaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer,” Cancer Research, vol. 70, no. 12, pp. 4995–5003, 2010. View at Publisher · View at Google Scholar · View at Scopus
  183. P. P. Gan, J. A. McCarroll, S. T. Po'Uha, K. Kamath, M. A. Jordan, and M. Kavallaris, “Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of βIII-tubulin,” Molecular Cancer Therapeutics, vol. 9, no. 5, pp. 1339–1348, 2010. View at Publisher · View at Google Scholar · View at Scopus
  184. A. L. Parker, M. Kavallaris, and J. A. McCarroll, “Microtubules and their role in cellular stress in cancer,” Frontiers in Oncology, vol. 4, article 153, 2014. View at Publisher · View at Google Scholar · View at Scopus
  185. G. Raspaglio, F. Filippetti, S. Prislei et al., “Hypoxia induces class III beta-tubulin gene expression by HIF-1α binding to its 3' flanking region,” Gene, vol. 409, no. 1-2, pp. 100–108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  186. M. De Donato, M. Mariani, L. Petrella et al., “Class III beta-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer,” Journal of Cellular Physiology, vol. 227, no. 3, pp. 1034–1041, 2012. View at Publisher · View at Google Scholar · View at Scopus
  187. I. Ojima, S. Chakravarty, T. Inoue et al., “A common pharmacophore for cytotoxic natural products that stabilize microtubules,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 8, pp. 4256–4261, 1999. View at Publisher · View at Google Scholar · View at Scopus
  188. M. St. George, A. T. Ayoub, A. Banerjee et al., “Designing and testing of novel taxanes to probe the highly complex mechanisms by which taxanes bind to microtubules and cause cytotoxicity to cancer cells,” PLoS ONE, vol. 10, no. 6, Article ID e0129168, 2015. View at Publisher · View at Google Scholar
  189. G. Höfle, N. Bedorf, H. Steinmetz, D. Schomburg, K. Gerth, and H. Reichenbach, “Epothilone A and B—novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution,” Angewandte Chemie, vol. 35, no. 13-14, pp. 1567–1569, 1996. View at Publisher · View at Google Scholar · View at Scopus
  190. M. Wartmann and K.-H. Altmann, “The biology and medicinal chemistry of epothilones,” Current Medicinal Chemistry: Anti-Cancer Agents, vol. 2, no. 1, pp. 123–148, 2002. View at Publisher · View at Google Scholar · View at Scopus
  191. K.-H. Altmann, G. Bold, G. Caravatti, A. Flörsheimer, V. Guagnano, and M. Wartmann, “Synthesis and biological evaluation of highly potent analogues of epothilones B and D,” Bioorganic and Medicinal Chemistry Letters, vol. 10, no. 24, pp. 2765–2768, 2000. View at Publisher · View at Google Scholar · View at Scopus
  192. D. M. Bollag, P. A. McQueney, J. Zhu et al., “Epothilones, a new class of microtubule-stabilizing agents with a taxol- like mechanism of action,” Cancer Research, vol. 55, no. 11, pp. 2325–2333, 1995. View at Google Scholar · View at Scopus
  193. C.-P. H. Yang, P. Verdier-Pinard, F. Wang et al., “A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence,” Molecular Cancer Therapeutics, vol. 4, no. 6, pp. 987–995, 2005. View at Publisher · View at Google Scholar · View at Scopus
  194. J. K. Peterson, C. Tucker, E. Favours et al., “In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models,” Clinical Cancer Research, vol. 11, part 1, no. 19, pp. 6950–6958, 2005. View at Publisher · View at Google Scholar · View at Scopus
  195. C. F. Brogdon, F. Y. Lee, and R. M. Canetta, “Development of other microtubule-stabilizer families: the epothilones and their derivatives,” Anticancer Drugs, vol. 25, no. 5, pp. 599–609, 2014. View at Publisher · View at Google Scholar · View at Scopus
  196. J. M. G. Larkin and S. B. Kaye, “Epothilones in the treatment of cancer,” Expert Opinion on Investigational Drugs, vol. 15, no. 6, pp. 691–702, 2006. View at Publisher · View at Google Scholar · View at Scopus
  197. K. De Geest, J. A. Blessing, R. T. Morris et al., “Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 149–153, 2010. View at Publisher · View at Google Scholar · View at Scopus
  198. S. L. Mooberry, G. Tien, A. H. Hernandez, A. Plubrukarn, and B. S. Davidson, “Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents,” Cancer Research, vol. 59, no. 3, pp. 653–660, 1999. View at Google Scholar · View at Scopus
  199. D. E. Pryor, A. O'Brate, G. Bilcer et al., “The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity,” Biochemistry, vol. 41, no. 29, pp. 9109–9115, 2002. View at Publisher · View at Google Scholar · View at Scopus
  200. C. D. Churchill, M. Klobukowski, and J. A. Tuszynski, “The unique binding mode of laulimalide to two tubulin protofilaments,” Chemical Biology & Drug Design, vol. 86, no. 2, pp. 190–199, 2015. View at Publisher · View at Google Scholar
  201. H. Lu, J. Murtagh, and E. L. Schwartz, “The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere),” Molecular Pharmacology, vol. 69, no. 4, pp. 1207–1215, 2006. View at Publisher · View at Google Scholar · View at Scopus
  202. P. A. Wender, M. K. Hilinski, N. Soldermann, and S. L. Mooberry, “Total synthesis and biological evaluation of 11-desmethyllaulimalide, a highly potent simplified laulimalide analogue,” Organic Letters, vol. 8, no. 7, pp. 1507–1510, 2006. View at Publisher · View at Google Scholar · View at Scopus
  203. A. E. Prota, K. Bargsten, P. T. Northcote et al., “Structural basis of microtubule stabilization by laulimalide and peloruside A,” Angewandte Chemie, vol. 53, no. 6, pp. 1621–1625, 2014. View at Publisher · View at Google Scholar · View at Scopus
  204. C. Madiraju, M. C. Edler, E. Hamel et al., “Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin,” Biochemistry, vol. 44, no. 45, pp. 15053–15063, 2005. View at Publisher · View at Google Scholar · View at Scopus
  205. L. L. Vollmer, M. Jiménez, D. P. Camarco et al., “A simplified synthesis of novel dictyostatin analogues with in vitro activity against epothilone B-resistant cells and antiangiogenic activity in zebrafish embryos,” Molecular Cancer Therapeutics, vol. 10, no. 6, pp. 994–1006, 2011. View at Publisher · View at Google Scholar · View at Scopus
  206. K. R. Brunden, N. M. Gardner, M. J. James et al., “MT-stabilizer, dictyostatin, exhibits prolonged brain retention and activity: potential therapeutic implications,” ACS Medicinal Chemistry Letters, vol. 4, no. 9, pp. 886–889, 2013. View at Publisher · View at Google Scholar · View at Scopus
  207. T. Lindel, P. R. Jensen, W. Fenical et al., “ChemInform abstract: eleutherobin, a new cytotoxin that mimics paclitaxel (taxol) by stabilizing microtubules,” ChemInform, vol. 28, no. 51, 2010. View at Publisher · View at Google Scholar
  208. B. H. Long, J. M. Carboni, A. J. Wasserman et al., “Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol),” Cancer Research, vol. 58, no. 6, pp. 1111–1115, 1998. View at Google Scholar · View at Scopus
  209. E. Hamel, B. W. Day, J. H. Miller et al., “Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly,” Molecular Pharmacology, vol. 70, no. 5, pp. 1555–1564, 2006. View at Publisher · View at Google Scholar · View at Scopus
  210. Y. Nakao, S. Yoshida, S. Matsunaga, and N. Fusetani, “(Z)-sarcodictyin A, a new highly cytotoxic diterpenoid from the soft coral Bellonella albiflora,” Journal of Natural Products, vol. 66, no. 4, pp. 524–527, 2003. View at Publisher · View at Google Scholar · View at Scopus
  211. A. L. Risinger, F. J. Giles, and S. L. Mooberry, “Microtubule dynamics as a target in oncology,” Cancer Treatment Reviews, vol. 35, no. 3, pp. 255–261, 2009. View at Publisher · View at Google Scholar · View at Scopus
  212. R. Kaur, G. Kaur, R. K. Gill, R. Soni, and J. Bariwal, “Recent developments in tubulin polymerization inhibitors: an overview,” European Journal of Medicinal Chemistry, vol. 87, pp. 89–124, 2014. View at Publisher · View at Google Scholar · View at Scopus
  213. Z. Liu, P. Xu, T. Wu, and W. Zeng, “Microtubule-targeting anticancer agents from marine natural substance,” Anti-Cancer Agents in Medicinal Chemistry, vol. 14, no. 3, pp. 409–417, 2014. View at Publisher · View at Google Scholar · View at Scopus
  214. J. Cortes and J. Baselga, “Targeting the microtubules in breast cancer beyond taxanes: the epothilones,” Oncologist, vol. 12, no. 3, pp. 271–280, 2007. View at Publisher · View at Google Scholar · View at Scopus
  215. L. Vahdat, “Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms,” Oncologist, vol. 13, no. 3, pp. 214–221, 2008. View at Publisher · View at Google Scholar · View at Scopus